브리아셀 테라퓨틱스BCTX 주가

BriaCell Therapeutics Receives Sixth Positive Recommendation From Independent Data Safety Monitoring Board For Its Pivotal Phase 3 Bria-ABC Trial Of Bria-IMT Plus Immune Checkpoint Inhibitor

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent

BriaCell Therapeutics Presents Positive Clinical Data From Three Clinical Data Poster Presentations, Three Publication-Only Abstracts At 2026 ASCO Annual Meeting

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce positive

BriaCell Therapeutics Announces Progress In Developing Bria-OVA+, Next Gen, Personalized, Off-The-Shelf, Cell-Based Immunotherapy For Ovarian Cancer

BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer, is designed with

BriaCell Therapeutics Completes Manufacturing Clinical Supplies Of Bria-PROS+ For Prostate Cancer

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed

BriaCell Therapeutics Adds Penn Medicine's Abramson Cancer Center As Clinical Trial Site In BriaCell's Ongoing Pivotal Phase 3 Clinical Study

Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology

BriaCell Therapeutics\ Pivotal Phase 3 Bria-ABC Trial Enrolls 230 Participants

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that its pivotal

BriaCell Therapeutics Receives FDA Clearance To Initiate Clinical Evaluation Of Bria-BRES+, Its Next Generation Cell-Based Immunotherapy For Metastatic Breast Cancer

FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation personalized immunotherapy

[8-K] 중대 사건 — 8-K

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K